Docoh
Loading...

ATRS Antares Pharma

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

Company profile

Ticker
ATRS
Exchange
CEO
Robert Apple
Employees
Incorporated
Location
Fiscal year end
Former names
ANTARES PHARMA INC, ANTARES PHARMA INC, ANTARES PHARMA INC /MN/, MEDI JECT CORP /MN/
SEC CIK
IRS number
411350192

ATRS stock data

(
)

Calendar

6 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
13 Jun 21 Apple Robert F Common Stock Payment of exercise Dispose F No No 4.45 40,892 181.97K 2,396,630
13 Jun 21 Graham Peter J Common Stock Payment of exercise Dispose F No No 4.45 14,790 65.82K 594,431
11 Jun 21 Apple Robert F Common Stock Payment of exercise Dispose F No No 4.45 58,317 259.51K 2,437,522
11 Jun 21 Graham Peter J Common Stock Payment of exercise Dispose F No No 4.45 23,010 102.39K 609,221
10 Jun 21 Garrity Thomas J Common Stock Grant Aquire A No No 4.42 25,452 112.5K 249,858
10 Jun 21 Garrity Thomas J Stock Option Common Stock Grant Aquire A No No 4.42 48,542 214.56K 48,542
10 Jun 21 Apple Robert F Common Stock Grant Aquire A No No 4.42 248,869 1.1M 2,495,839
10 Jun 21 Apple Robert F Stock Option Common Stock Grant Aquire A No No 4.42 474,629 2.1M 474,629
10 Jun 21 Greenleaf Peter Common Stock Grant Aquire A No No 4.42 25,452 112.5K 79,645
10 Jun 21 Greenleaf Peter Stock Option Common Stock Grant Aquire A No No 4.42 48,542 214.56K 48,542

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

48.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 171 174 -1.7%
Opened positions 23 24 -4.2%
Closed positions 26 13 +100.0%
Increased positions 56 50 +12.0%
Reduced positions 47 53 -11.3%
13F shares
Current Prev Q Change
Total value 474.06M 354.57M +33.7%
Total shares 82.51M 72.98M +13.1%
Total puts 145.7K 232.9K -37.4%
Total calls 301K 240.2K +25.3%
Total put/call ratio 0.5 1.0 -50.1%
Largest owners
Shares Value Change
BLK Blackrock 12.08M $49.63M +2.1%
Rubric Capital Management 8.72M $35.85M +144.3%
Vanguard 8.29M $34.09M +2.3%
STT State Street 4.71M $19.36M +15.4%
FMR 3.84M $15.77M -18.1%
Sargent Investment 3.6M $14.79M +3.2%
Centric Wealth Management 3.34M $13.72M -4.1%
Geode Capital Management 2.65M $10.91M +8.6%
Nuveen Asset Management 2.39M $9.81M +96.7%
Oracle Investment Management 1.9M $7.81M 0.0%
Largest transactions
Shares Bought/sold Change
Rubric Capital Management 8.72M +5.15M +144.3%
HealthInvest Partners AB 0 -1.72M EXIT
Nuveen Asset Management 2.39M +1.17M +96.7%
Amundi Pioneer Asset Management 1.13M +1.13M NEW
MS Morgan Stanley 1.62M +996.99K +159.6%
Putnam Investments 1.72M +922.4K +115.4%
FMR 3.84M -846.26K -18.1%
STT State Street 4.71M +627.34K +15.4%
Venator Capital Management 550K +550K NEW
State Board Of Administration Of Florida Retirement System 602.6K +543.43K +918.4%

Financial report summary

?
Management Discussion
  • Revenue from product sales was $29.1 million and $27.1 million for the three months ended March 31, 2021 and 2020, respectively, an increase of 8% on a period over period basis. The increase in product revenue was driven primarily by increased sales of our proprietary product XYOSTED® and an increase in sales of epinephrine auto injectors to Teva, offset by a decrease in sales of other partnered products, as detailed below.
  • Sales of our proprietary products XYOSTED®, OTREXUP® and NOCDURNA®, which are presented net of estimated product returns and sales allowances, generated revenue of $18.7 million and $12.6 million for the three months ended March 31, 2021 and 2020, respectively, representing a 49% increase on a comparative basis. The increase in proprietary product sales for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020 was principally attributable to continued growth in prescriptions and sales of XYOSTED®, and to new sales of NOCDURNA®, which we in-licensed and began detailing in the fourth quarter of 2020.
  • We also manufacture and sell devices, components and fully assembled and packaged product to our partners. Partnered product sales were $10.4 million and $14.5 million for the three months ended March 31, 2021 and 2020, respectively, representing a decrease of 28% on a comparative basis. The net decrease in partnered product sales for the three months ended March 31, 2021 as compared to the same period in 2020 is primarily attributable to a decrease in production and sales of Makena product for AMAG and sales of sumatriptan product to Teva, offset by an increase in sales of epinephrine auto injectors to Teva.  
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accrued, appeal, began, carefully, complement, component, comprehensive, conform, convenience, discrete, endocrinology, favorably, formulation, forward, heading, Imitrex, incorporated, IND, Investigational, Note, oncology, path, prior, proportionally, Quarterly, reclassified, reintroduction, released, shown, soft, STATdose, submission, taxable, tolerability, unmet, unrecognized
Removed: account, accounted, achieved, achievement, agency, amortized, API, apply, approximated, assessment, asset, ASU, binding, Biotechnology, Board, borrowed, bridging, capitalizing, Carlo, carried, chain, Clarifying, cloud, collaborative, computing, conduct, criteria, curtail, deferral, delay, depend, depreciation, difficult, earn, economy, eligibility, enhance, evaluating, exceed, expensed, Factor, FASB, goal, greater, grow, Hedging, heightening, historically, hold, hosted, human, identify, impairment, implementation, implementing, imposed, Index, injectable, intent, intention, interaction, issuance, JCR, limit, longer, making, manufacturer, measure, measurement, meeting, methodology, minimal, mitigation, Monte, Mylan, Nasdaq, negatively, obligated, ordinary, participant, positive, predict, primary, productivity, protection, rapidly, recipient, recommendation, reimbursement, rely, resulting, reusable, shareholder, shutdown, side, simulation, small, smaller, software, source, standard, suitable, supportable, target, tied, trade, Treasury, TSR, ultimate, uncertain, utilizing, vendor

Patents

GRANT
Utility
Cartridge retainer for an injection device
25 May 21
A cartridge retainer comprises a sleeve having a distal end a proximal end and a longitudinal axis extending between the distal end and the proximal end.
APP
Utility
Administration of Testosterone Compositions
13 May 21
The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
APP
Utility
Needle Assisted Injection Device Having Reduced Trigger Force
22 Apr 21
An injector includes a trigger mechanism including: a trigger member disposed about an axis having an aperture and a protrusion, and a ram assembly having a ram configured to pressurize a medicament container for expelling a medicament therefrom, the ram assembly further having a trigger engagement member configured to engage the aperture of the trigger member when the trigger member is in a pre-firing condition; an energy source associated with the ram for powering the ram to expel the medicament; and a user-operable firing-initiation member having an aperture engaged with the protrusion of the trigger member and operable for causing an axial translation of the trigger member in a proximal direction from the pre-firing condition to a firing condition in which the trigger engagement member is released from the retaining portion to allow the energy source to fire the ram.
GRANT
Utility
Needle assisted injection administration of testosterone compositions
9 Feb 21
The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
GRANT
Utility
Injection device with cammed ram assembly
2 Feb 21
An exemplary embodiment of injector includes a trigger mechanism, an energy source, and a user-operable firing-initiation member.